Literature DB >> 25409329

Topical sevoflurane and healing of a post-operative surgical site superinfected by multi-drug-resistant Pseudomonas aeruginosa and susceptible Staphylococcus aureus in an immunocompromised patient.

Juan Luis Rueda-Martínez1, Manuel Gerónimo-Pardo, Angel Martínez-Monsalve, María Martínez-Serrano.   

Abstract

BACKGROUND: Infections caused by multi-drug-resistant organisms are too common and represent a therapeutic challenge. Topical application of sevoflurane may be useful for the treatment of cutaneous infections, as this general anesthetic has antimicrobial properties in vitro. CASE REPORT: A 43-year-old male patient received a liver transplant because of cirrhosis caused by hepatitis C. The surgical site was infected initially by multi-drug-resistant Pseudomonas aeruginosa that was susceptible to colistin, but parenteral administration of this antibiotic led to deterioration of renal function and was discontinued. The incision did not heal with daily lavage and debridement and was superinfected with Staphylococcus aureus. The off-label use of liquid sevoflurane in the form of site irrigations was followed by healing and closure of the site. This healing could be attributable to the mixed effect of three possible actions of sevoflurane: Direct antimicrobial effect, local analgesic effect that improved the quality of the dressings, and a direct vasodilator effect that, in theory, increased the supply of nutrients to the incision bed.
CONCLUSIONS: The use of liquid sevoflurane on sites infected by microorganisms resistant to conventional antibiotics appears to be an attractive therapeutic option that deserves future research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25409329     DOI: 10.1089/sur.2013.079

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  7 in total

1.  Topical sevoflurane for chronic venous ulcers infected by multi-drug-resistant organisms.

Authors:  Adrián Imbernón-Moya; Francisco Javier Ortiz-de Frutos; Mónica Sanjuan-Alvarez; Isabel Portero-Sanchez; Raúl Merinero-Palomares; Victoria Alcazar
Journal:  Int Wound J       Date:  2017-07-23       Impact factor: 3.315

2.  Chronic venous ulcer treatment with topical sevoflurane.

Authors:  Adrián Imbernón; Cristina Blázquez; Ana Puebla; Micaela Churruca; Alejandro Lobato; Marcela Martínez; Antonio Aguilar; Miguel A Gallego
Journal:  Int Wound J       Date:  2015-07-21       Impact factor: 3.315

3.  Palliative analgesia with topical sevoflurane in cancer-related skin ulcers: a case report.

Authors:  F Dámaso Fernández-Ginés; Manuel Cortiñas-Sáenz; Ana Navajas-Gómez de Aranda; Maria Del Carmen Navas-Martinez; José Antonio Morales-Molina; Francisco Sierra-García; Héctor Mateo-Carrasco
Journal:  Eur J Hosp Pharm       Date:  2018-01-11

4.  Healing of chronic venous ulcer with topical sevoflurane.

Authors:  Adrian Imbernon-Moya; Francisco Javier Ortiz-de Frutos; Mónica Sanjuan-Alvarez; Isabel Portero-Sanchez; Raúl Merinero-Palomares; Victoria Alcazar
Journal:  Int Wound J       Date:  2017-08-17       Impact factor: 3.315

5.  Pain, Quality of Life, and Functional Capacity With Topical Sevoflurane Application for Chronic Venous Ulcers: A Retrospective Clinical Study.

Authors:  Adrian Imbernon-Moya; Francisco J Ortiz-de Frutos; Monica Sanjuan-Alvarez; Isabel Portero-Sanchez; Raul Merinero-Palomares; Victoria Alcazar
Journal:  EJVES Short Rep       Date:  2017-09-14

Review 6.  Topical Sevoflurane: A Novel Treatment for Chronic Pain Caused by Venous Stasis Ulcers.

Authors:  Mayank Aranke; Cynthia T Pham; Melis Yilmaz; Jason K Wang; Vwaire Orhurhu; Daniel An; Elyse M Cornett; Alan David Kaye; Anh L Ngo; Farnad Imani; Reza Farahmand Rad; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Anesth Pain Med       Date:  2021-02-24

7.  Occupational exposure to sevoflurane following topical application to painful wounds.

Authors:  Dámaso Fernández-Ginés; Carmen Selva-Sevilla; Manuel Cortiñas-Sáenz; Manuel Gerónimo-Pardo
Journal:  Med Lav       Date:  2019-10-29       Impact factor: 1.275

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.